Holen Sie sich die Stockscreener-App
20.33
6.22%
1.19
Handel nachbörslich:
20.32
-0.010
-0.05%
Schlusskurs vom Vortag:
$19.14
Offen:
$19.78
24-Stunden-Volumen:
19.43M
Relative Volume:
0.60
Marktkapitalisierung:
$4.63B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
38.94
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+8.25%
1M Leistung:
+29.16%
6M Leistung:
-62.87%
1J Leistung:
-21.78%
1-Tages-Spanne:
$19.51
$20.37
1-Wochen-Bereich:
$18.64
$21.62
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
20.33 | 4.36B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.26 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.92 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.82 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
559.65 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers shares rise as investors refocus on growth outlook despite recent data-breach disclosure - Quiver Quantitative
Hims & Hers Advances a Consumer-Centric Digital Health Platform - The Globe and Mail
Hims & Hers Health (NYSE:HIMS) Shares Gap UpHere's Why - MarketBeat
Hims & Hers says limited data stolen in social engineering attack - Cybersecurity Dive
Hims & Hers Health stock climbs as price remains inside $18.90–$20.90 range - Traders Union
Hims & Hers Faces Investor Scrutiny Ahead of Quarterly Earnings - AD HOC NEWS
Best Healthcare Stocks To Add to Your WatchlistApril 5th - MarketBeat
2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Hims & Hers Health, Inc. (HIMS) And Encourages Shareholders to Reach Out | NYSE:HIMS | Press Release - Stockhouse
Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Hims & Hers Health, Inc. (HIMS) stock price, news, quote and history - Yahoo Finance UK
Hims & Hers Health, Inc. (HIMS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Hims Data Breach Tests Trust As Valuation Gap Attracts Investors - Yahoo Finance
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Dir - PharmiWeb.com
Novo partnership fuels long-term optimism for Hims & Hers Health, Inc. (HIMS) - MSN
Data Breach Alert: Edelson Lechtzin LLP Investigates Hims & Hers, Inc. Data Breach - GlobeNewswire Inc.
Data Breach Alert: Edelson Lechtzin LLP Investigates Hims & Hers, Inc. Data Breach - PR Newswire
Hims & Hers Health Faces Investor Lawsuit Over Alleged Misconduct - National Today
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc.HIMS - Business Wire
Hims & Hers hack: Telehealth company reports customer support system breach - The American Bazaar
Barclays raises PT on Hims & Hers Health (HIMS) stock - MSN
HIMS Stock Gains As FDA Reportedly Moves Toward Lifting Restrictions On Peptides - Stocktwits
Healthcare Stocks To Watch TodayApril 3rd - MarketBeat
Hims & Hers warns of data breach after Zendesk support ticket breach - BleepingComputer
Hims and Hers reveal cyberattack — customer support system hacked and personal info stolen, here's what we know - TechRadar
Here is what to know beyond why Hims & Hers Health, Inc. (HIMS) is a trending stock - MSN
Hims & Hers' Valuations Back To EarthRobust Monetization Trends Deserve Reiterated Buy - Seeking Alpha
Hims & Hers Health stock price forecast: sideways consolidation likely as HIMS falls 3.53% - Traders Union
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock - Yahoo Finance
HIMS stock gains as FDA reportedly moves toward lifting restrictions on peptides - MSN
AI for investors - MLQ.ai
Security Breach and Trade Policy Fears Weigh on Hims & Hers Stock - AD HOC NEWS
Should You Buy Hims Stock Today? - theglobeandmail.com
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
Hims & Hers flags suspicious activity linked to third‑party customer service vendor - TradingView
Hims & Hers Data Breach Exposes Customer Service Records - Claim Depot
Building Better Health: AI as the Operating System for Care - Hims & Hers Newsroom
Broad selling pressure keeps Hims & Hers stock restrained after telehealth expansion news - Traders Union
Hims & Hers Health, Inc. (HIMS) Outperforms Broader Market: What You Need to Know - MSN
US FDA clarifies policies on compounding of GLP-1 medicines - Reuters
Hims & Hers Health Inc (HIMS) Stock Price, Trades & News - GuruFocus
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - globenewswire.com
Hims & Hers Health Stock Short Interest Falls to 45.18% - Quiver Quantitative
-3.88% for Hims & Hers Health stock as oscillators give mixed signals near session low - Traders Union
Hims & Hers Stock Is Down 63% Over the Past 6 Months. Here’s Why the Valuation Still Looks Compelling - TIKR.com
Novo Partnership Fuels Long-Term Optimism for Hims & Hers Health, Inc. (HIMS) - Insider Monkey
Hims & Hers expands personalized digital healthcare platform - MSN
Hims & Hers Broadens Tailored Online Health Services Platform - Bitget
Hims & Hers Expands Personalized Digital Healthcare Platform - The Globe and Mail
Hims & Hers Health Inc (HIMS) Stock Price Up 6.42% on Mar 31 - GuruFocus
HIMS Gains as FDA Revisits Rules on Compounding Pharmacies - GuruFocus
Did Hims & Hers' Novo Nordisk GLP-1 Partnership Just Shift Hims & Hers Health's (HIMS) Investment Narrative? - Sahm
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Hims Hers Health Inc-Aktie (HIMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Okupe Oluyemi | Chief Financial Officer |
Mar 20 '26 |
Sale |
23.77 |
9,217 |
219,067 |
318,789 |
| Becklund Irene | PAO |
Mar 17 '26 |
Sale |
24.69 |
5,529 |
136,511 |
8,752 |
| Boughton Soleil | Chief Legal Officer |
Mar 17 '26 |
Sale |
24.69 |
4,812 |
118,808 |
308,831 |
| Chi Michael | Chief Operating Officer |
Mar 17 '26 |
Sale |
24.69 |
97,289 |
2,402,065 |
407,282 |
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):